Biofrontera Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls
Wall Street analysts changed ratings on top names. Check our analyst ratings page for full updates. THG, BFRI covered.
Top Wall Street analysts upgraded STUB, PGNY, AMT, and BAP stocks and raised their price targets. See what other analysts think of these stocks.
Benchmark analyst Bruce D. Jackson downgrades Biofrontera (NASDAQ:BFRI) from Buy to Speculative Buy and maintains the price target from $3 to $3.
Biofrontera Inc (BFRI) reports a 17% revenue increase and significant margin expansion, while navigating increased expenses and regulatory uncertainties.
Biofrontera Inc. (BFRI) Q1 2026 Earnings Call May 14, 2026 11:00 AM EDTCompany ParticipantsHermann Lubbert - CEO, President & ChairmanGeorge Jones -...
Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -127.78% and +6.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Biofrontera Inc. reported Q1 2026 revenue of $10.08M and EPS of -$0.41, missing analyst estimates by 3.6% and 249%, respectively.
Presentation Operator MessageOperator Good day, and welcome to Biofrontera Inc. First Quarter 2026 Financial Results and Business Update Conference Call. [Operator Instructions] Please note this
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.12) by 272.73 percent. This is a 12.77 percent increase over losses of $(0.47) per share from
Woburn, MA, May 14, 2026 -- Biofrontera Inc. , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial...
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +10.00% and -59.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis Awareness DayThis social media–driven initiative invites people to wear a hat, share a photo,...
WOBURN, Mass., May 08, 2026 -- Biofrontera Inc. , a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy , announces it will report financial...
Rapport Therapeutics, Inc. (RAPP) delivered earnings and revenue surprises of +24.66% and 0.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Biofrontera Inc (BFRI) reports a profitable Q4 with significant revenue growth and strategic transactions enhancing future prospects.
Biofrontera Inc (BFRI) reports a profitable Q4 with significant revenue growth and strategic transactions enhancing future prospects.
Biofrontera (NASDAQ:BFRI) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.20 by 146.15 percent. This is a 352.63 percent increase over losses of $(0.19) per share from the
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-12upcoming | -0.04 | — | — |
| 2026-05-14 | -0.05 | -0.41 | -720.00% |
| 2026-03-19 | 0.10 | 0.50 | +398.10% |
| 2025-11-12 | -0.56 | -0.57 | -1.55% |
| 2025-08-13 | -0.39 | -0.57 | -45.10% |
| 2025-05-15 | -0.29 | -0.51 | -75.31% |
| 2025-03-21 | -0.07 | -0.23 | -231.44% |
| 2024-11-13 | -0.94 | -0.81 | +13.43% |
| 2024-08-14 | -0.35 | -1.08 | -207.34% |
| 2024-05-15 | -0.71 | -1.69 | -137.61% |
| 2024-03-15 | -0.85 | -0.68 | +19.91% |
| 2023-11-09 | -3.34 | -3.16 | +5.35% |
| 2023-08-11 | -4.08 | -6.07 | -48.85% |
| 2023-05-12 | -3.40 | -3.22 | +5.35% |
| 2023-03-13 | -2.20 | -5.00 | -127.18% |
| 2022-11-14 | -5.80 | -5.24 | +9.69% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BFRI | -17.96% | -1.01% | +55.44% | +57.65% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -20.93% | +3.63% | +58.88% | +44.96% |